




Infographic

505(b)(2) Products Global Market Overview




505b2 Approved Data

- Drugs by Disease Names
- Drugs by Disease Group
- Drugs by Company
- Drugs by Country
- Trials by Phase
- Drugs by Therapeutic Class
- Trials by Therapeutic Area
- Trials by Disease
- Trials by Sponsor




Drugs by Disease Names (Showing top 20)




- 4 Hypertension, unspecified
- 3 Cancer, lung, non-small cell
- 3 Depression, major depressive disorder
- 3 Pain, nociceptive, general
- 2 Cancer, breast
- 2 Cancer, pancreatic
- 2 Not applicable
- 2 Pain, musculoskeletal, unspecified
- 2 Schizoaffective disorder
- 2 Schizophrenia
- 2 Spasticity
- 1 Acromegaly
- 1 Addiction, alcohol
- 1 Addiction, nicotine
- 1 Agitation, Alzheimer's disease
- 1 Alzheimer's disease
- 1 Anaesthesia, adjunct
- 1 Bipolar disorder
- 1 Cancer, biliary
- 1 Cancer, cervical

Drugs by Disease Group




Drugs by Company (Showing top 20)




- 3 IntelGenx
- 3 Sun Pharma Advanced Research
- 2 Daewoong Pharmaceutical
- 2 Mallinckrodt
- 2 Relief Therapeutics Holding
- 1 AcelRx
- 1 Acer Therapeutics
- 1 Adare Pharma Solutions
- 1 Alembic Pharmaceuticals
- 1 Amryt Pharma
- 1 Asklepion Pharmaceuticals
- 1 Avenir Wellness Solutions
- 1 Axsome Therapeutics
- 1 Azurity Pharmaceuticals
- 1 Chiesi
- 1 China Medical System
- 1 Currax Pharmaceuticals
- 1 Daiichi Sankyo
- 1 Dr. Falk Pharma
- 1 Eagle Pharmaceuticals

Drugs by Country

(Showing top 20)




Trials by Phase




Drugs by Therapeutic Class (Showing top 20)

- 5 Reformulation, fixed-dose combinations
- 4 Antidepressant
- 4 Reformulation, oral, other
- 3 Analgesic, opioid
- 3 Anticancer, other
- 3 Antihypertensive, renin system
- 3 Muscle relaxant
- 3 Reformulation, modified-release, <=24hr
- 3 Reformulation, modified-release, immediate
- 3 Reformulation, other
- 2 Analgesic, other
- 2 Antihypertensive, other
- 2 Antipsychotic
- 2 Dependence treatment
- 2 Reformulation technology
- 2 Reformulation, modified-release, other
- 2 Reformulation, optimized, microencapsulate
- 2 Reformulation, optimized, nanoparticles
- 1 Analgesic, NSAID
- 1 Anti-inflammatory




Trials by Therapeutic Area




Trials by Disease (Showing top 20)

- 31 CNS: Pain (nociceptive)
- 19 Oncology: Breast
- 14 CNS: Schizophrenia
- 14 Infectious Disease: Onychomycosis
- 12 CNS: Depression
- 12 Oncology: Lung, Non-Small Cell
- 9 Cardiovascular: Hypertension
- 9 Metabolic/Endocrinology: Growth Disorders
- 9 Oncology: Ovarian
- 8 CNS: Movement Disorders
- 7 Autoimmune/Inflammation: Hepatic Fibrosis
- 7 Oncology: Pancreas
- 6 Cardiovascular: Dyslipidemia
- 6 Metabolic/Endocrinology: NAFLD
- 5 CNS: Alzheimer's Disease
- 4 CNS: Migraine
- 4 Oncology: Bladder
- 4 Oncology: Cervical
- 4 Oncology: Neuroendocrine
- 3 CNS: Alcohol Dependence



Trials by Sponsor (Showing top 20)






505b2 Pipeline Data

- Drugs by Disease Names
- Drugs by Disease Group
- Drugs by Company
- Drugs by Country
- Trials by Phase
- Drugs by Therapeutic Class
- Trials by Therapeutic Area
- Trials by Disease
- Trials by Sponsor




Drugs by Disease Names (Showing top 20)




- 5 Pain, nociceptive, general
- 5 Parkinson's disease
- 4 Alzheimer's disease
- 4 Cancer, breast
- 4 Cancer, renal
- 4 Pain, post-operative
- 3 Addiction, alcohol
- 3 Addiction, narcotic/opiate
- 3 Cancer, bladder
- 3 Cancer, leukaemia, chronic myelogenous
- 3 Cancer, lung, non-small cell
- 3 Cancer, ovarian
- 3 Fibromyalgia
- 3 Inflammatory disease, unspecified
- 3 Non-alcoholic steatohepatitis
- 3 Pain, neuropathic, general
- 2 Acne
- 2 Agitation, Alzheimer's disease
- 2 Allergy, unspecified
- 2 Anaphylaxis

Drugs by Disease Group




Drugs by Company (Showing top 20)




- 3 Aquestive Therapeutics
- 3 Daré Bioscience
- 3 XSpray
- 2 Acasti Pharma
- 2 Grand Pharmaceutical Group
- 2 IntelGenx
- 2 Intellipharma
- 2 Invea Therapeutics
- 2 Lipocine
- 2 Luye Pharma Group
- 2 MedinCell
- 2 Nanology
- 2 Surface Pharmaceuticals
- 2 Tetra Bio-Pharma
- 2 Timber Pharmaceuticals, Inc
- 2 Viatris
- 1 10xBio
- 1 3SBio
- 1 Aldeyra Therapeutics
- 1 Alternavida

Drugs by Country (Showing top 20)




Trials by Phase




Drugs by Therapeutic Class (Showing top 20)

- 19 Reformulation, other
- 18 Reformulation, oral, other
- 11 Analgesic, other
- 10 Anticancer, other
- 10 Ophthalmological, other
- 8 Neurological
- 8 Reformulation, fixed-dose combinations
- 8 Reformulation, modified-release, other
- 6 Antiparkinsonian
- 6 Reformulation, parenteral, other
- 5 Dependence treatment
- 5 GI inflammatory/bowel disorders
- 5 Musculoskeletal
- 4 Anti-inflammatory
- 4 Cognition enhancer
- 4 Hepatoprotective
- 4 Reformulation, dermal, topical
- 4 Reformulation, implant
- 4 Reformulation, modified-release, >24hr
- 4 Reformulation, optimized, nanoparticles




Trials by Therapeutic Area




Trials by Disease (Showing top 20)

- 32 CNS: Pain (neuropathic)
- 29 CNS: Pain (nociceptive)
- 23 CNS: Parkinson's Disease
- 11 Metabolic/Endocrinology: NAFLD
- 11 Oncology: Leukemia, Acute Myelogenous
- 10 CNS: Schizophrenia
- 10 Oncology: Bladder
- 9 Oncology: Soft Tissue Sarcoma
- 8 Autoimmune/Inflammation: Hepatic Fibrosis
- 8 CNS: Narcolepsy
- 8 Oncology: Pancreas
- 7 CNS: Post Traumatic Stress Disorder (PTSD)
- 7 Infectious Disease: Respiratory Infections
- 7 Metabolic/Endocrinology: Diabetic Complications
- 7 Oncology: Unspecified Cancer
- 6 Cardiovascular: Dyslipidemia
- 6 CNS: Alzheimer's Disease
- 6 CNS: Opioid Use Disorder (OUD)
- 6 Oncology: Breast
- 5 Autoimmune/Inflammation: Osteoarthritis




Trials by Sponsor (Showing top 20)






505b2 Deals Alliance from 2021

- Eton Pharmaceuticals Sells Its Hospital Products to Dr. Reddy's Laboratories
- BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved Elyxyb for the Acute Treatment of Migraine; Completes Rights Acquisition
- Journey Enters into a Definitive Agreement with Dr. Reddy's to Develop and Commercialize DFD-29 for Rosacea
- Nicox Partners with Laboratorios Grin to Bring Zerivate to Mexico
- Lupin Announces Partnership to Commercialize Endoceutics' Intrarosa in Canada



Deal Date	Deal Title
-----------	------------



Eton Pharmaceuticals Sells Its Hospital Products to Dr. Reddy's Laboratories

Deal Type	Deal Characteristics	Company Name	
Alliance	Includes Royalty or Profit Split Information Marketing (Licensing)	Dr. Reddy's Laboratories Ltd. Eton Pharmaceuticals, Inc.	
Lisensee	Lisenser	Product Name	Disease Group
Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories Ltd.	Eton Pharmaceuticals, Inc. Eton Pharmaceuticals, Inc. Eton Pharmaceuticals, Inc.	Biorphen Rezipres	Cardiovascular Gastroenterology (Non Inflammatory Bowel Disease)
Indication	Phase At Time of Deal	Target	Molecule
Hypotension/Shock Hypotension/Shock Liver Failure / Cirrhosis Gastroenterologic Disorders	Approved Approved Approved	Alpha 1 Adrenergic Receptor Beta Adrenergic Receptors Norepinephrine (Noradrenaline) Alpha Adrenergic Receptors	Small Molecule Small Molecule

Deal Date	Deal Title
-----------	------------



BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved Elyxyb for the Acute Treatment of Migraine; Completes Rights Acquisition

Deal Type	Deal Characteristics	Company Name		
Alliance	Includes Royalty or Profit Split Information Marketing (Licensing)	Dr. Reddy's Laboratories Ltd. BioDelivery Sciences International, Inc.		
Lisensee	Lisenser	Product Name	Disease Group	
BioDelivery Sciences International, Inc.	Dr. Reddy's Laboratories Ltd.	Elyxyb	Neurology	
Indication	Phase At Time of Deal	Target	Molecule	
Migraine and Other Headaches	Approved	Cyclooxygenase 2 (COX2) / Prostaglandin-Endoperoxide Synthase 2 (PTGS2)	Small Molecule	

Deal Date	Deal Title
-----------	------------



Journey Enters into a Definitive Agreement with Dr. Reddy’s to Develop and Commercialize DFD-29 for Rosacea

Deal Type	Deal Characteristics	Company Name
-----------	----------------------	--------------

Alliance	R&D and Marketing (Licensing)	Dr. Reddy's Laboratories Ltd. Journey Medical Corp.
----------	-------------------------------	---

Lisensee	Lisenser	Product Name	Disease Group
----------	----------	--------------	---------------

Journey Medical Corp.	Dr. Reddy's Laboratories Ltd.	Minolira	Dermatology
-----------------------	-------------------------------	----------	-------------

Indication	Phase At Time of Deal	Target	Molecule
------------	-----------------------	--------	----------

Rosacea	II	Protein synthesis Bacterial ribosome	Small Molecule
---------	----	--------------------------------------	----------------

Deal Date	Deal Title
-----------	------------



Nicox Partners with Laboratorios Grin to Bring Zerviate to Mexico

Deal Type	Deal Characteristics	Company Name
-----------	----------------------	--------------

Alliance

Includes Royalty or Profit Split Information|Intra-Biotech Deal|R&D and Marketing (Licensing)

Nicox S.A.|Lupin Limited|Laboratorios Grin SA de CV

Lisensee	Lisenser	Product Name	Disease Group
----------	----------	--------------	---------------

Laboratorios Grin SA de CV

Nicox S.A.

Zerviate

Ophthalmology

Indication	Phase At Time of Deal	Target	Molecule
------------	-----------------------	--------	----------


Allergic Conjunctivitis (Ophthalmology)

Approved

Histamine H1 Receptor (HRH1)

Small Molecule

Deal Date	Deal Title
-----------	------------



Lupin Announces Partnership to Commercialize Endoceutics’ Intrarosa in Canada

Deal Type	Deal Characteristics	Company Name	
Alliance	Marketing (Licensing)	Endoceutics Inc. Lupin Limited	
Lisensee	Lisenser	Product Name	Disease Group
Lupin Limited	Endoceutics Inc.	Intrarosa	Endocrine Obstetrics/ Gynecology
Indication	Phase At Time of Deal	Target	Molecule
Female Sexual Arousal Disorder Vaginal Atrophy	Approved	Androgen receptors Estrogen	Small Molecule



Thank You



CITELINE.COM

